

3 March 2026

## Osteopore secures distribution rights for autologous dentin graft technology process, expanding regenerative dental portfolio

### Highlights

- Osteopore has secured distribution rights to a new autologous process for dental socket preservation, and other indications requiring bone regeneration for Singapore, which also serves as a potential launchpad into the ASEAN/ APAC markets.
- This process enables chairside conversion of extracted teeth into mineralized and demineralized autologous dentin graft within minutes.
- Autologous dentin can be an attractive option for dental practitioners because it is osteoinductive and osteoconductive and may even be suitable for immune-compromised patients.
- The Asia Pacific dental bone graft market is expected to reach USD 303m (~AUD 425m) by 2030, growing at a Compound Annual Growth Rate of 10.9% between 2024 and 2030 <sup>1</sup>.
- Singapore has 899 private dental clinics and 248 public dental clinics spread across the country <sup>2</sup>.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: OSX; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants has secured a 2-year distribution agreement to introduce a new autologous process for dental socket preservation powered by the Smart Dentin Grinder® for Singapore, which

<sup>1</sup> <https://www.grandviewresearch.com/horizon/outlook/dental-bone-grafts-and-substitutes-market/asia-pacific?>

<sup>2</sup> <https://www.moh.gov.sg/resources-statistics/singapore-health-facts/health-facilities>

also serves as a launchpad to expand into the ASEAN/ APAC markets, which comprises of 11 countries.

This new autologous process convert a patient's freshly extracted tooth into particulate autologous dentin graft material chairside in approximately 7 minutes. The processed dentin retains its natural collagen matrix and endogenous growth factors, including bone morphogenetic proteins (BMPs), which contribute to its osteoinductive and osteoconductive properties, and promotes new bone formation.

In addition, it may also be appropriate for immune-compromised or medically-compromised patients.

The current practice in Singapore is the use of xenografts, which typically originate from porcine or bovine sources. Xenografts in dental bone grafting may present various issues that limit the efficacy of socket preservation, such as slow resorption, variable remodeling, residual graft persistence, and limited osteoinductivity, among others. In contrast, the autologous source of the dentin coupled with its unique properties acts as an optimal matrix for predictable bone regeneration and long term site repair.

This autologous dentin extraction protocol was developed by KometaBio Inc, a U.S.-based company focused in the area of dental and oral rehabilitation. The KometaBio Smart Dentin Grinder® is cleared for use by the US FDA as a medical device.

Key terms of the distribution agreement:

- Exclusivity: Non-exclusive
- Period: 2 years, until 28 February 2028
- Territory: Singapore
- Upon request, parties will review the business and results to expand the territory to include the ASEAN/ APAC markets where KometaBio has no representation.

Following the agreement, Osteopore shall undertake the necessary product registration process in line with Singapore regulations.

The Asia Pacific dental bone graft market is expected to reach USD 303m (~AUD 425m) by 2030, growing at a Compound Annual Growth Rate of 10.9% between 2024 and 2030<sup>3</sup>. According to the statistics published by the Ministry of Health<sup>4</sup>, Singapore has 899 private dental clinics and 248 public dental clinics spread across the country.

**Commenting on the latest addition of complementary products, CEO Dr Yujing Lim said:**

“Our mission has always been clear: to augment patient outcomes through the use of regenerative medicine. Autologous dentin works on the principle of regenerative medicine, and has demonstrated strong potential to be a good market fit in Singapore.

“Importantly, this strengthens our product portfolio for dentistry, and complements our existing products for Guided Bone Regeneration”, said Dr Lim.

**END**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer  
Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Mark Leong**

Executive Chairman  
Osteopore Limited

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

<sup>3</sup> <https://www.grandviewresearch.com/horizon/outlook/dental-bone-grafts-and-substitutes-market/asia-pacific?>

<sup>4</sup> <https://www.moh.gov.sg/resources-statistics/singapore-health-facts/health-facilities>

### About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.